Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Sponsor

Shanghai Zhongshan Hospital (Other)

Overall Status

Recruiting

CT.gov ID

NCT04943679

Collaborator

(none)

Enrollment

Location

42.5

Anticipated Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of Pegylated Interferon Alfa-2b and anti-PD-1/PD-L1 antibodies for patients with advanced hepatocellular carcinoma.

Condition or Disease	Intervention/Treatment	Phase
Hepatocellular Carcinoma	Drug: Anti-PD-1/PD-L1 Drug: PEG-Interferon Alfa

Detailed Description

This is a study of combination anti-PD-1/PD-L1 antibodies and peginterferon alfa-2b for adult patients (≥18) with advanced hepatocellular carcinoma. Each 21 day dosing period will constitute a cycle.

Pegylated Interferon Alfa-2b has been proven to prolong the survival of HCC patients. Pegylated Interferon Alfa-2b is given subcutaneously, weekly during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.

Anti-PD-1/PD-L1 antibodies (including pembrolizumeb, nivolumab, sintilimab, toripalimab, camrelizumeb, tislelizumab and atezolizumab etc.) are given intravenously at assigned dose. Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.

This study is aimed to evaluate the safety and efficacy of the combination of Pegylated Interferon Alfa-2b and PD-1/PD-L1 mAb in unresectable late-stage HCC patients.

Study Design

Study Type:

Observational

Anticipated Enrollment :

15 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Phase I/II Study of Anti-PD-1/PD-L1 Antibodies Combined With Pegylated Interferon Alfa-2b in Patients With Advanced-Stage Hepatocellular Carcinoma

Actual Study Start Date :

Jun 15, 2021

Anticipated Primary Completion Date :

Dec 31, 2024

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years	Drug: Anti-PD-1/PD-L1 Intravenous injection for up to 2 years Drug: PEG-Interferon Alfa 3 µg/kg every week by subcutaneous injection for up to 2 years Other Names: Pegasys

Arm

Intervention/Treatment

Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b

Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years

Drug: Anti-PD-1/PD-L1

Intravenous injection for up to 2 years

Drug: PEG-Interferon Alfa

3 µg/kg every week by subcutaneous injection for up to 2 years

Other Names:

Pegasys

Outcome Measures

Primary Outcome Measures

Incidence of adverse events [Up to 30 days after last treatment dose]
Safety will be monitored by addressing and recording all adverse events (AEs), serious adverse events (SAEs) and specific laboratory abnormalities (worst grade). Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.

Secondary Outcome Measures

Objective response rate(ORR) [2 years]
Evaluated by researchers based on the RECIST 1.1 standard
Progression free survival(PFS) [ Time Frame: 2 years ] [2 years]
Evaluated by researchers based on the RECIST 1.1 standard
To the relief time (TOR) [2 years]
Evaluated by researchers based on the RECIST 1.1 standard
Duration of relief(DOR) [2 years]
Evaluated by researchers based on the RECIST 1.1 standard
Disease Control Rate (DCR) [2 years]
Evaluated by researchers based on the RECIST 1.1 standard
9-month survival rate [9-month]
Evaluated by researchers based on the RECIST 1.1 standard
12-month survival rate [12-month]
Evaluated by researchers based on the RECIST 1.1 standard

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 90 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

≥18 years old, male or female
Advanced hepatocellular carcinoma (cannot be removed or metastasized) diagnosed clinically or pathologically, at least one measurable lesion without local treatment, Child-Pugh A ;Barcelona Clinic Liver Cancer(BCLC) staging is stage B or C
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Patient has given written informed consent.
The function of important organs meets the requirements
Expected survival ≥12 weeks
Non-surgical sterilization or women of childbearing age need to use a medically-accepted contraceptive (such as an intrauterine device, contraceptive or condom) during the study period and within 3 months after the end of the study treatment period.

Exclusion Criteria:

1.The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid Hyperfunction; patients with vitiligo; complete remission of asthma in childhood, can be included without any intervention after adulthood; asthma patients who require bronchodilators for medical intervention cannot be included); 2.The patient is using immunosuppressive agents or systemic hormonal therapy to achieve immunosuppressive purposes (agents amount > 10 mg / day of prednisone or other therapeutic hormones), and continue to use within 2 weeks before enrollment; 3.Have clinical symptoms or disease that are not well controlled 4.Significant clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior to randomization 5.Arterial/venous thrombosis in the first 6 months of randomization 6.According to the investigator, the patient has other factors that may affect the results of the study or lead to the termination of the study, such as alcohol abuse, drug abuse, other serious diseases (including mental illness) requiring combined treatment, and serious laboratory abnormalities.，with family or social factors, it will affect the safety of patients.

7.Liver tumor burden greater than 50% of the total liver volume, or patients who have previously undergone liver transplantation;Known for a history of central nervous system metastasis or hepatic encephalopathy;Severe allergic reactions to other monoclonal antibodies;